Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease often with limited or no therapeutic options.
$210.23
-$4.19 (-1.95%)
EOD Oct 16, 2026
The business is unprofitable at the operating level (-10.08% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue grew 4.9%, steady but not accelerating. Margins contracted 27.7pp, which offsets some of the top-line progress.
ROIC dropped from 5.72% to -3.40%, capital efficiency is deteriorating. Operating margin contracted 27.7pp YoY, cost discipline may be slipping.
14.4x earnings, 8.6x FCF. The multiple is below average. Either the market is pricing in deterioration you should investigate, or there's genuine value here.
Price History
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$4.60B
▲ +4.9% YoY
Net Income (TTM)
$941M
▼ -163.6% YoY
Op. Margin
19.49%
▼ -27.7pp YoY
ROIC
7.41%
▼ -9.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$1.59B
▼ -4.5% YoY
Op. Cash Flow (TTM)
$1.66B
▼ -2.9% YoY
Net Debt
$2.78B
Cash & Equiv.
$1.62B
5Y CAGR: +12.5%
5Y CAGR: +8.0%
Continue Research
SourceComputed from the 10-Q filed 27 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.
Price from market data, last close as of 16 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.
Is Jazz Pharmaceuticals (JAZZ) overvalued?
At a P/E of 14.4 and a price-to-free-cash-flow of 8.6, Jazz Pharmaceuticals (JAZZ) trades below a two-stage DCF intrinsic value of about $888.32 per share, so at $210.23 the stock looks undervalued (322.5% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Jazz Pharmaceuticals scores 64/100 on Intrinsiqq's quality scorecard (a solid business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.
Frequently asked
What is Jazz Pharmaceuticals's fair value?+
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $888.32 per share for JAZZ, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $666.24. At today's $210.23, that puts the stock about 322.5% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
Is Jazz Pharmaceuticals a high-quality business?+
Jazz Pharmaceuticals scores 64 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which makes it a solid business on these measures. Recent fundamentals include a 19.5% operating margin and a 7.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
Is Jazz Pharmaceuticals a good stock to buy right now?+
That depends on valuation and quality together, not either alone. JAZZ currently trades below its estimated intrinsic value and scores 64/100 on quality (solid). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.
Related stocks: Pharmaceutical Preparations
Spot a number that looks wrong?
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.